Opko Health Inc. - OPK STOCK NEWS

BioReference Health, one of the largest specialty laboratories in the U.S., announced it will offer the CINtec® PLUS Cytology test from Roche Diagnostics, the only FDA-approved dual-stain triage test for HPV-positive patients. The test is available for women aged 30-65 when cytology results are NILM and HR HPV tests are positive. By utilizing dual-stain biomarker technology, the CINtec PLUS Cytology test aims to improve disease detection and clinical outcomes, potentially reducing follow-up visits. The announcement underscores BioReference's commitment to enhancing cervical cancer screening and patient care.

OPKO Health, Inc. (Nasdaq: OPK) will participate in the 41st Annual J.P. Morgan Healthcare Conference from January 9-12, 2023, in San Francisco. The management will conduct one-on-one meetings and present on January 11 at 4:30 p.m. Pacific time. The presentation will be available via live webcast and later for replay on the OPKO Health website. As a multinational biopharmaceutical and diagnostics company, OPKO aims to lead in rapidly growing markets through innovative technologies and development capabilities.

OPKO Health reported a net loss of $86.1 million or $0.11 per share for Q3 2022, compared to a net income of $28.7 million or $0.04 per diluted share in Q3 2021. Total revenues were $179.7 million, down from $385.8 million, largely attributed to a significant decrease in COVID-19 testing volume at BioReference Laboratories. Notably, the company’s operating loss reached $87.8 million, influenced by increased costs linked to acquisitions and product development. However, OPKO anticipates higher royalty payments related to Pfizer’s NGENLA as it gains additional pricing approvals.

OPKO Health, Inc. (NASDAQ: OPK) will report its operating and financial results for the three and nine months ended September 30, 2022, on November 8, 2022. The announcement will include a business update alongside financial results and guidance, shared during a conference call at 4:30 p.m. Eastern time. Participants are encouraged to pre-register to access the call efficiently. OPKO aims to solidify its position in rapidly growing markets through its proprietary technologies and development expertise.

OPKO Health, Inc. (NASDAQ: OPK) announces the retirement of Jon R. Cohen, M.D., as Executive Chairman and CEO of BioReference Laboratories. He will serve as an advisor until December 2022 and as a consultant for nine additional months. Craig Allen, previously President and COO, is appointed Interim CEO. Cohen, recognized for leading BioReference during the COVID-19 pandemic and establishing Scarlet Health, leaves a legacy of growth and innovation. Allen brings over 25 years of lab industry experience, aiming for long-term profitable growth.

OPKO Health reports its Q2 2022 financial results with consolidated revenues of $309.9 million, down from $442.4 million year-over-year. The company experienced an operating loss of $10.7 million, contrasted with an operating income of $5.6 million in Q2 2021. Significant highlights include the acquisition of ModeX Therapeutics for $300 million in OPKO stock and $85 million in milestone payments from Pfizer for the launch of NGENLA. Loss per share stood at $0.14, compared to $0.03 in the previous year. Cash and equivalents were at $210.5 million.

OPKO Health (NASDAQ: OPK) will report its operating and financial results for Q2 2022 on August 4, 2022, after U.S. markets close. The company will hold a conference call at 4:30 p.m. Eastern Time to discuss these results and provide financial guidance. Investors are encouraged to pre-register for easier access to the call. A replay of the conference call will be available until August 11, 2022. OPKO is focused on establishing industry-leading positions in rapidly growing markets through its innovative biopharmaceutical and diagnostics expertise.

OPKO Health, Inc. (NASDAQ: OPK) will participate in the 2022 Jefferies Healthcare Conference from June 8-10 in New York City. Management's fireside chat is scheduled for June 9 at 8:00 a.m. Eastern time, and it will be webcast live, with a replay available on OPKO’s website. This event highlights OPKO's commitment to engaging with investors and showcasing its innovative biopharmaceutical and diagnostics initiatives.

OPKO Health, Inc. (NASDAQ: OPK) reported its financial results for Q1 2022, revealing consolidated revenues of $329.2 million, down from $545.2 million in Q1 2021. The company incurred a net loss of $55.4 million, or $0.08 per share, compared to a net income of $31.1 million in the previous year. Key business highlights include the acquisition of ModeX Therapeutics for $300 million in OPKO stock and the sale of GeneDx to Sema4, which provided $150 million in cash proceeds. Notably, OPKO expects to receive $85 million in milestone payments from Pfizer in Q2 2022.